[ad_1] <br><a href="https://news.google.com/rss/articles/CBMimgFodHRwczovL3NpbXBseXdhbGwuc3Qvc3RvY2tzL3VzL3BoYXJtYWNldXRpY2Fscy1iaW90ZWNoL25hc2RhcS1ydm5jL3JldmFuY2UtdGhlcmFwZXV0aWNzL25ld3MvcmV2YW5jZS10aGVyYXBldXRpY3MtaW5jcy1uYXNkYXFydm5jLWVhcm5pbmdzLWhhdmVudC1lc2NhcGVk0gGeAWh0dHBzOi8vc2ltcGx5d2FsbC5zdC9zdG9ja3MvdXMvcGhhcm1hY2V1dGljYWxzLWJpb3RlY2gvbmFzZGFxLXJ2bmMvcmV2YW5jZS10aGVyYXBldXRpY3MvbmV3cy9yZXZhbmNlLXRoZXJhcGV1dGljcy1pbmNzLW5hc2RhcXJ2bmMtZWFybmluZ3MtaGF2ZW50LWVzY2FwZWQvYW1w?oc=5" target="_blank" rel="noopener">Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Earnings Haven't Escaped The Attention Of Investors</a> <font color="#6f6f6f">Merely Wall St</font> <br>[ad_2] <br><a href="https://news.google.com/rss/articles/CBMimgFodHRwczovL3NpbXBseXdhbGwuc3Qvc3RvY2tzL3VzL3BoYXJtYWNldXRpY2Fscy1iaW90ZWNoL25hc2RhcS1ydm5jL3JldmFuY2UtdGhlcmFwZXV0aWNzL25ld3MvcmV2YW5jZS10aGVyYXBldXRpY3MtaW5jcy1uYXNkYXFydm5jLWVhcm5pbmdzLWhhdmVudC1lc2NhcGVk0gGeAWh0dHBzOi8vc2ltcGx5d2FsbC5zdC9zdG9ja3MvdXMvcGhhcm1hY2V1dGljYWxzLWJpb3RlY2gvbmFzZGFxLXJ2bmMvcmV2YW5jZS10aGVyYXBldXRpY3MvbmV3cy9yZXZhbmNlLXRoZXJhcGV1dGljcy1pbmNzLW5hc2RhcXJ2bmMtZWFybmluZ3MtaGF2ZW50LWVzY2FwZWQvYW1w?oc=5">Source link </a>